BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 10575406)

  • 1. Risk factors for erythema nodosum leprosum.
    Manandhar R; LeMaster JW; Roche PW
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24 months WHO-MDT.
    Balagon M; Saunderson PR; Gelber RH
    Lepr Rev; 2011 Sep; 82(3):213-21. PubMed ID: 22125929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India.
    Pocaterra L; Jain S; Reddy R; Muzaffarullah S; Torres O; Suneetha S; Lockwood DN
    Am J Trop Med Hyg; 2006 May; 74(5):868-79. PubMed ID: 16687695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
    Feuth M; Brandsma JW; Faber WR; Bhattarai B; Feuth T; Anderson AM
    Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M; Berhe D
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological characteristics of leprosy reactions: 15 years experience from north India.
    Kumar B; Dogra S; Kaur I
    Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):125-33. PubMed ID: 15301592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
    Sampaio EP; Malta AM; Sarno EN; Kaplan G
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histoid leprosy: a retrospective study of 40 cases from India.
    Kaur I; Dogra S; De D; Saikia UN
    Br J Dermatol; 2009 Feb; 160(2):305-10. PubMed ID: 19016704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.
    Rea TH; Sieling PA
    Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):316-27. PubMed ID: 9934358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
    de Carsalade GY; Achirafi A; Flageul B
    Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactional states in multibacillary Hansen disease patients during multidrug therapy.
    Nery JA; Vieira LM; de Matos HJ; Gallo ME; Sarno EN
    Rev Inst Med Trop Sao Paulo; 1998; 40(6):363-70. PubMed ID: 10436656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of bacillary clearance in multibacillary leprosy patients with multidrug therapy.
    Kumar A; Girdhar A; Girdhar BK
    Acta Leprol; 2003; 12(3):123-8. PubMed ID: 15040703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Histoid leprosy with erythema nodosum leprosum].
    Alioua Z; Sbai M; Elhaouri M; Bouzidi A; Boudi O; Ghfir M; Benomar S; Sedrati OL
    Acta Leprol; 2003; 12(3):107-11. PubMed ID: 15040700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reaction cases treated at the Regional Leprosy Training and Research Institute, Aska, Orissa: a retrospective analysis.
    Santaram V; Porichha D
    Indian J Lepr; 2004; 76(4):310-20. PubMed ID: 16119141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiologic characteristics of leprosy reactions.
    Scollard DM; Smith T; Bhoopat L; Theetranont C; Rangdaeng S; Morens DM
    Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):559-67. PubMed ID: 7868954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy.
    Rea TH
    Int J Lepr Other Mycobact Dis; 2001 Dec; 69(4):318-27. PubMed ID: 12035293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy].
    Rodríguez G; Pinto R; López F; Gómez Y
    Biomedica; 2009 Mar; 29(1):18-24. PubMed ID: 19753835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some unusual type 2 reactions in leprosy.
    Ramesh V; Pahwa M
    Int J Dermatol; 2010 Feb; 49(2):172-5. PubMed ID: 20465641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, the Philippines, and Korea.
    Cellona RV; Fajardo TT; Kim DI; Hah YM; Ramasoota T; Sampattavanich S; Carrillo MP; Abalos RM; dela Cruz EC; Ito T
    Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):1-11. PubMed ID: 2181040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.